Tennyson Nathan, Mendenhall William M, Morris Christopher G, Huang Emina H, Zlotecki Robert A
Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, FL, USA.
Clin Med Res. 2012 Nov;10(4):224-9. doi: 10.3121/cmr.2012.1072. Epub 2012 Sep 20.
To evaluate the efficacy of transanal excision (TAE) combined with radiotherapy for rectal adenocarcinoma, assess the ability of pretreatment endoscopic ultrasound (EUS) to predict failures, and determine the prognostic value of downstaging and complete pathological response.
Retrospective outcomes study.
Radiation oncology clinic.
Thirty-eight patients with rectal adenocarcinoma.
The medical records of patients treated with radiotherapy from 1998 to 2008 and followed for a median of 5.9 years were reviewed.
Kaplan-Meier estimates of freedom from selected endpoints at 5 years after treatment were: overall survival, 79%; cause-specific survival, 91%; local control, 90%; and freedom from distant metastasis, 76%. Seven patients (21%) had eventual abdominoperineal resection or lower anterior resection, four patients had local recurrence, and three patients had incomplete treatment or poor margins. T3 lesions clinically staged by EUS were a predictor of local failure (P=0.0110), but not distant metastasis (P=0.35). Patients with either a pathological or clinical T3 lesion did not have a significantly greater rate of metastasis (P=0.096). Patients who were downstaged did not have a significantly different rate of local recurrence or metastasis. Patients who experienced a complete pathological response did not have a significantly different rate of local control or distant metastasis.
Patients with early-stage rectal lesions who undergo preoperative or postoperative radiation and TAE have similar outcomes to those who undergo abdominoperineal resection; local recurrence was higher for patients with T3 lesions when both were compared. Abdominal surgery should be considered for these patients. TAE is reasonable when patients are unwilling or unable to tolerate the morbidity of traditional transabdominal surgery.
评估经肛门切除术(TAE)联合放疗治疗直肠腺癌的疗效,评估治疗前内镜超声(EUS)预测治疗失败的能力,并确定降期和完全病理缓解的预后价值。
回顾性结局研究。
放射肿瘤诊所。
38例直肠腺癌患者。
回顾1998年至2008年接受放疗并随访中位时间为5.9年的患者的病历。
治疗后5年Kaplan-Meier估计的特定终点无病生存率为:总生存率79%;病因特异性生存率91%;局部控制率90%;无远处转移率76%。7例患者(21%)最终接受了腹会阴联合切除术或低位前切除术,4例患者出现局部复发,3例患者治疗不完全或切缘不佳。EUS临床分期为T3的病变是局部失败的预测因素(P=0.0110),但不是远处转移的预测因素(P=0.35)。病理或临床T3病变的患者转移率没有显著更高(P=0.096)。降期的患者局部复发或转移率没有显著差异。经历完全病理缓解的患者局部控制或远处转移率没有显著差异。
接受术前或术后放疗及TAE的早期直肠病变患者与接受腹会阴联合切除术的患者预后相似;比较两者时,T3病变患者的局部复发率更高。这些患者应考虑行腹部手术。当患者不愿意或无法耐受传统经腹手术的并发症时,TAE是合理的。